An 8-year follow-up of anti-insulin antibodies in diabetic children: relation to insulin autoantibodies, HLA type, beta-cell function, clinical course and type of insulin therapy.
In 105 children and adolescents with IDDM, insulin antibodies were detected as a percentage of radiolabelled insulin both at onset of disease and during the first 8 years of treatment. At diagnosis, 29 patients (27%) were insulin autoantibody positive (IAA+). An inverse relationship was found between IAA levels and age at diagnosis. No significant correlation was seen between IAA positivity and HLA antigens, while there was a negative correlation between IAA and C-peptide levels in the second year of the disease. The percentage of insulin antibody (IA) positive patients increased after insulin administration, with a maximum peak between the first and second year of the disease. The IA response to insulin therapy was similar in IAA+ and IAA- patients, while it was greater in younger children. No relationship was found between IA levels and haemoglobin A1c values, daily insulin requirement, HLA and early complications. No difference in either percentage of positivity or IA levels was seen in patients treated continually for the first 5 years of the disease with monocomponent porcine insulin or human insulin. A negative correlation was found between IA and C-peptide levels in the first and second years of the disease. In conclusion, we have shown that, even after many years of disease, neither IAA nor IA, induced in equal measures by current human insulin preparations, have significant effects on the clinical course of the disease.
Salardi
S
S
First Paediatric Clinic, University of Bologna, Italy.
Cacciari
E
E
Steri
L
L
Donati
S
S
Mandini
M
M
Gualandi
S
S
Mantovani
W
W
Zucchini
S
S
D000293:Adolescent; D000906:Antibodies / Q000097:blood*; D000917:Antibody Formation; D001323:Autoantibodies / Q000097:blood; D002096:C-Peptide / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D006680:HLA Antigens / Q000097:blood*; D006801:Humans; D007223:Infant; D007328:Insulin / Q000276:immunology* / Q000627:therapeutic use; D008297:Male; D013997:Time Factors
D000906:Antibodies; D001323:Autoantibodies; D002096:C-Peptide; D006680:HLA Antigens; D007328:Insulin